## **Presently Pending Claims**

Language to be added has been **bolded and underlined**, while language to be deleted has been **bolded and striken-through**.

21. (Currently amended) A compound represented by the structural formula I

$$R^{1}$$
 $N$ 
 $R^{10}$ 
 $R^{10}$ 

or a pharmaceutically acceptable salt or solvate thereof; wherein:

R<sup>1</sup> is

§—M—R⁴ ;

R<sup>2</sup> is selected from the group consisting of H, alkyl, aryl, arylalkyl, heteroarylalkyl, alkylketone, arylketone, alkyl, haloalkyl, cycloalkyl, cycloalkyl, alkylsulfonyl, arylsulfonyl, alkoxyalkyl, or amide;

R<sup>3</sup> is selected from the group consisting of **aryl**, 6-membered heteroaryl, **fluorenyl**; and **diphenylmethyl**, 6-membered heteroaryl-N-oxide,

or 6-membered heteroaryl or heteroaryl-N-oxide is pyrimidine or pyrimidine-N-oxide respectively, each of which is optionally substituted with 1-4 substituents which can be the same or different and are independently selected from the group consisting of R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup> and R<sup>15</sup>;

R<sup>4</sup> is 1-3 substituents selected from the group consisting of H, halo, alkyl, haloalkyl, alkoxy, cycloalkyl, amide, CF<sub>3</sub>, OCF<sub>3</sub>, aryl, heteroaryl, -XR<sup>7</sup>, -CN, -CO<sub>2</sub>H, -

 $CO_2R^{22}$ ,  $R^8$ -aryl( $C_1$ - $C_6$ )alkyl-,  $R^8$ -heteroaryl( $C_1$ - $C_6$ )alkyl-,  $-C(O)NR^{21}R^{22}$ ,  $-C(O)NH_2$ , wherein  $R^4$  can be the same or different and is independently selected when there is more than one  $R^4$  present;

 $R^5$  is selected from the group consisting of H, arylalkyl,  $(C_1-C_6)$ alkyl,  $R^8$ -aryl( $C_1-C_6$ )alkyl-,  $R^8$ -heteroaryl( $C_1-C_6$ )alkyl-,  $-SO_2$ -( $C_1-C_6$ )alkyl-,  $-SO_2$ -( $C_3$ - $C_6$ )cycloalkyl,  $-SO_2$ -aryl,  $R^8$ -aryl- $SO_2$ -, -C(O)-( $C_1-C_6$ )alkyl, -C(O)-( $C_4-C_6$ )cycloalkyl,  $R^8$ -aryl-C(O)-,  $-C(O)NR^{21}R^{22}$ , and  $-SO_2NR^{21}R^{22}$ ;

R<sup>6</sup> is H, -(C<sub>1</sub>-C<sub>6</sub>)alkyl, or -(C<sub>1</sub>-C<sub>6</sub>)haloalkyl;

R<sup>7</sup> is selected from the group consisting of aryl, substituted aryl, heteroaryl, alkyl, haloalkyl and cycloalkyl;

R<sup>8</sup> is 1, 2 or 3 substituents selected from the group consisting of H, halo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -CF<sub>3</sub>, -OCF<sub>3</sub>, CH<sub>3</sub>C(O)-, -CN, CH<sub>3</sub>SO<sub>2</sub>-,

CF<sub>3</sub>SO<sub>2</sub>- and -NH<sub>2</sub>, wherein R<sup>8</sup> can be the same or different and is independently selected when there are more than one R<sup>8</sup> present;

 $R^9$ ,  $R^{10}$  and B can be the same or different and are each independently selected from the group consisting of hydrogen, ( $C_1$ - $C_6$ )alkyl, and -( $C_1$ - $C_6$ )haloalkyl;

 $R^{11}$  and  $R^{12}$  can be the same or different and are each independently selected from the group consisting of  $(C_1-C_6)$ alkyl,  $-(C_1-C_6)$ haloalkyl, halogen,  $-NR^{19}R^{20}$ , -OH,  $CF_3$ ,  $-OCH_3$ , -O-acyl, and  $-OCF_3$ ;

 $R^{13}$  is selected from the group consisting of hydrogen,  $R^{11}$ , H, phenyl, -NO<sub>2</sub>, -CN, -CH<sub>2</sub>F, -CHF<sub>2</sub>, -CHO, -CH=NO $\underline{R}^{19}$ R<sub>19</sub>, pyridyl-N-oxide, pyrimidinyl, pyrazinyl, N( $\underline{R}^{20}$ R<sub>29</sub>)CON $\underline{R}^{20}$ R<sup>21</sup>R<sub>29</sub>R<sub>21</sub>, -NHCONH(chloro-(C<sub>1</sub>-C<sub>6</sub>)alkyl), -NHCONH((C<sub>3</sub>-C<sub>10</sub>)-cycloalkyl(C<sub>1</sub>-C<sub>6</sub>)alkyl), -NHCO(C<sub>1</sub>-C<sub>6</sub>)alkyl, -NHCOCF<sub>3</sub>, -NHCOCF<sub>3</sub>, -NHSO<sub>2</sub>N((C<sub>1</sub>-C<sub>6</sub>)alkyl)<sub>2</sub>, -NHSO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, -N(SO<sub>2</sub>CF<sub>3</sub>)<sub>2</sub>, -NHCO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl, -SR<sup>22</sup>, -SOR<sup>22</sup>, -SO<sub>2</sub>R<sup>22</sup>, -SO<sub>2</sub>NH(C<sub>1</sub>-C<sub>6</sub> alkyl), -OSO<sub>2</sub>(C<sub>1</sub>-C<sub>6</sub>)alkyl, -OSO<sub>2</sub>CF<sub>3</sub>, hydroxy(C<sub>1</sub>-C<sub>6</sub>)alkyl, -CONR<sup>19</sup>R<sup>20</sup>, -CON(CH<sub>2</sub>CH<sub>2</sub>-O-CH<sub>3</sub>)<sub>2</sub>, -OCONH(C<sub>1</sub>-C<sub>6</sub>)alkyl, -CO<sub>2</sub>R<sup>19</sup>R<sub>19</sub>, -Si(CH<sub>3</sub>)<sub>3</sub> and -B(OC(CH<sub>3</sub>)<sub>2</sub>)<sub>2</sub>;

 $R^{14}$  is selected from the group consisting of (C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>1</sub>-C<sub>6</sub>)haloalkyl -NH<sub>2</sub> and  $R^{15}$ -phenyl;

 $R^{15}$  is 1-3 substituents selected from the group consisting of hydrogen, (C<sub>1</sub>-C<sub>6</sub>)alkyl, -(C<sub>1</sub>-C<sub>6</sub>)haloalkyl, -CF<sub>3</sub>, -CO<sub>2</sub>R<sup>20</sup>, -CN, (C<sub>1</sub>-C<sub>6</sub>)alkoxy and halogen; wherein R<sup>15</sup> can be the same or different and is independently selected when there are more than one R<sup>15</sup> present;

R<sup>16</sup> and R<sup>17</sup> can each be the same or different and are each independently selected from the group consisting of hydrogen and (C<sub>1</sub>-C<sub>6</sub>)alkyl, or

R<sup>16</sup> and R<sup>17</sup> together are a C<sub>2</sub>-C<sub>5</sub> alkylene group and with the carbon to which they are attached from a spiro ring of 3 to 6 carbon atoms;

 $R^{19}$ ,  $R^{20}$  and  $R^{21}$  can each be the same or different and are each independently selected from the group consisting of H,  $(C_1-C_6)$ alkyl and  $(C_3-C_6)$ cycloalkyl;

 $R^{22}$  is selected from the group consisting of  $(C_1-C_6)$ alkyl,  $-(C_1-C_6)$ haloalkyl,  $(C_2-C_6)$ hydroxyalkyl,  $(C_2-C_6)$ alkylene,  $(C_3-C_6)$ cycloalkyl, aryl and aryl $(C_1-C_6)$ alkyl-;

A is selected from the group consisting of H,  $(C_1-C_6)$  alkyl, and  $(C_2-C_6)$  alkenyl. M is aryl **or heteroaryl** optionally substituted with  $R^4$ ;

## Q is CH or N; and

X is selected from the group consisting of CH<sub>2</sub>, SO<sub>2</sub>, SO, S, and O, with the following proviso:

when  $R^1$  is phenyl, pyridyl, thiophenyl or naphthyl,  $R^2$  cannot be H, -(C<sub>1</sub>-C<sub>6</sub>)alkyl or -C(O)-(C<sub>1</sub>-C<sub>6</sub>)alkyl.

22. (Currently amended) A compound having the structural formula I according to claim 21 or a pharmaceutically acceptable salt or solvate thereof, wherein R<sup>9</sup>, R<sup>10</sup> and B are H, A is -CH<sub>3</sub>, and R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are as defined in the following table:

#	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>
8	Br		2 2
9	, i		Z Z
10	CF <sub>3</sub>		N N
11	CF <sub>3</sub> O		N N

,	~		Attorney Docke
12	CI		Z Z Z
13	CF <sub>3</sub> N		N N
14	F		N N
15	CF <sub>3</sub> O		N+-0.
16	CF <sub>3</sub> N		Z+-0
17	Br		N N
18	CI		N N
19	Br Br	F	N N
20	CF <sub>3</sub>		Z Z Z
21	777		N N
22	7		N N

		T	Attorney Docket
23			N N
24	OCF <sub>3</sub>		N N
25	F F		N N
26	CI		N N
27	F CI		N N
28	Br CH <sub>3</sub>		N N N
29	MeO CI		N N N
30	Br CH <sub>3</sub>		N
31	Ž'i F		N N N
32	Cl Zi		Z Z Z
33	OMe		N N

		 Attorney Docke
34	F <sub>3</sub> C Ti	N N N N N N N N N N N N N N N N N N N
35	CI CF <sub>3</sub>	N N N
36	F F	Z Z
37	MeO	Z Z Z
38	Br CF <sub>3</sub>	N N
39	CH <sub>3</sub>	N N
40	EtO	N N
41	Et	N N
42	C F	N N N N N N N N N N N N N N N N N N N
43	PhO	Z Z Z
44	CN CN	N N N
4 <del>6</del>	N N N / Bn	N

		·	Attorney Docker
50	MeSO <sub>2</sub>		Z Z
51	CI		N N
<b>52</b>	Br		N N
53	, , , , , , , , , , , , , , , , , , ,		N N
58			
59	HO <sub>2</sub> C		N
60	HO <sub>2</sub> C		N
61	H <sub>2</sub> N Ti		N
62			N
63	N N		N N N N N N N N N N N N N N N N N N N
65	O NH NH		N N
66	N H		N N N

Serial No. 10/629,466 Attorney Docket No. IN01481KB

,			Attorney Docket
67	HO NH Ti		N N
68	A P C Ti		N N
69	CF <sub>3</sub>		N N
70	F <sub>3</sub> CO		N N
71	Br N		N N N N N N N N N N N N N N N N N N N
<del>72</del>			N
73	CI		N N
74			N N
75		(CH <sub>2</sub> ) <sub>2</sub>	N N
76	F <sub>3</sub> C N		N N N N N N N N N N N N N N N N N N N
77	N N		N N
78	CINN		N N N

		· · · · · · · · · · · · · · · · · · ·	Attorney Docke
79	F		N N
80		N.	7,7,7 4 Z
8-1	F <sub>3</sub> CO		N+.0.
82	CF <sub>3</sub> N		N+-O'
83	F <sub>3</sub> C N		N+.O.
84		Z	N+·O
85	Br		N+·O
86		\\{	N
87	Br		N
88	Br Tri	- X	N N

,	T	·	Altorney Docke
89	Br Ti	N	N
90		Z Z	Z X
91	MeO CI		N N
92	CI		N N
93	T'A'		, , , M
94	OMe		-1/2 N
95	Br CF <sub>3</sub>		
96	CH <sub>3</sub>		
97	Br	N.	
98	Br		N N
99	EtO Li		N N
100	Et Ti		N

Serial No. 10/629,466 Attorney Docket No. IN01481KB

			Attorney Docke
101	F F		N
102	MeO		N N N
103	Br	<u></u>	N N
104	F		, , , , , , , , , , , , , , , , , , ,
105	PhO		N N
106			Z Z
107	The state of the s		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
108	N N		N N
109	N N		N
110	Z Z		, , , , , , , , , , , , , , , , , , ,
111	CI	GH₃	N N

23. (Currently amended) A compound according to claim 22 wherein  ${\sf R}^1,\,{\sf R}^2$  and  ${\sf R}^3$  each represent:

Serial No. 10/629,466 Attorney Docket No. IN01481KB

11.		R <sup>2</sup>	Attorney Doo
# <u>9</u>	R	H H	K N
remainden a martin de la martin			N N
10	CF <sub>3</sub>		N N
11	CF <sub>3</sub> O		Z
12	CI		Z Z
13	CF <sub>3</sub>		N N N N N N N N N N N N N N N N N N N
14	F		Z Z Z
16	CF <sub>3</sub> N		N+·O
17	Br		N N
28	Br CH <sub>3</sub>		N N
29	MeO CI		N N
31	F Ti		N N

Serial No. 10/629,466 Attorney Docket No. IN01481KB

			Attorney Doc
36	F Yi		Z Z
37	MeO		NN
39	CH <sub>3</sub>		N N
40	EtO		N N
50	MeSO <sub>2</sub>		N N
61	H <sub>2</sub> N Ti		N N
68	AN POLICE OF THE PROPERTY OF T		N N
69	CF <sub>3</sub> N		N N
70	F <sub>3</sub> CO		N N
71	Br N		N
80		N	N N
81	F <sub>3</sub> CO		N+.O.

Serial No. 10/629,466 Attorney Docket No. IN01481KB

		·	Attorney Dod
82	CF <sub>3</sub> N		Attorney Doc
90		N N N N N N N N N N N N N N N N N N N	N N
91	MeO CI		N N N N N N N N N N N N N N N N N N N
93	F T		N N
96	CH <sub>3</sub>		N N N
99	EtO Zi		N N
100	Et		
101	F	{	N N
<del>102</del>	MeO		N N

24. (Currently amended) A compound according to claim 23 represented by the structural formulae:

and

## or a pharmaceutically acceptable salt or solvate thereof.

- 25. (Currently amended) A pharmaceutical composition comprising one or more compounds of claim 21 or a pharmaceutically acceptable salt or solvate thereof.
- 26. (Currently amended) A pharmaceutical composition comprising one or more compounds of claim 24 or a pharmaceutically acceptable salt or solvate thereof.
- 27. (Previously presented) The pharmaceutical composition according to claim 25 further comprising one or more pharmaceutically acceptable carriers.
- 28. (Previously presented) The pharmaceutical composition according to claim 26 further comprising one or more pharmaceutically acceptable carriers.

- 29. (Currently amended) The pharmaceutical composition according to claim 25, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds <u>or a pharmaceutically acceptable salt or solvate thereof.</u>
- 30. (Currently amended) The pharmaceutical composition according to claim 26, wherein said pharmaceutical composition contains a therapeutically effective amount of said one or more compounds <u>or a pharmaceutically acceptable salt or solvate thereof</u>.

31-40. (Previously canceled)